辉瑞公司宣布， Lyrica（普瑞巴林胶囊）已在欧洲通过批准。该产品为成人广泛性焦虑障症治疗药，主要治疗由日常压力导致的长期忧虑、紧张和抑郁等症状。   约2000名受试患者参加的一系列临床试验结果显示，使用该药治疗后最常见的副作用为头晕和瞌睡。   Lyrica（普瑞巴林胶囊）在美国获准用于治疗癫痫病和糖尿病疼痛。它的作用机理是减少人体内向神经细胞输送的钙。    Lyrica Generic Name: pregabalin (pre GAB a lin) Brand Names: Lyrica FDA Approves Drug for Neuropathy Pain D. Trecroci Dec 1, 2005 Pfizer, Inc., announced on September 21, 2005, that Lyrica (pregabalin) capsules are now available for the management of neuropathic pain associated with diabetic peripheral neuropathy (DPN), postherpetic neuralgia (PHN) and adjunctive treatment of partial onset seizures in adults with epilepsy. “Until now, we’ve had limited options to treat patients with these types of neuropathic pain,” says Edgar Ross, MD, director of the Pain Management Center at Brigham and Women’s Hospital in Boston. “I have seen the benefits of Lyrica in providing rapid and sustained pain relief among my patients in the clinical trials.” According to Pfizer, Lyrica is the first treatment approved by the U.S. Food and Drug Administration to treat two distinct forms of neuropathic pain and is the first new antiepileptic drug introduced in five years. Lyrica is available in pharmacies nationwide. For more information, log on to www.lyrica.com. Source: Pfizer, Inc. What Is Neuropathic Pain? Neuropathic pain is caused by nerve damage that can result from underlying conditions, such as diabetes or shingles. Nearly half of the 18 million Americans with diabetes will develop some form of diabetic neuropathy over the course of their disease and will suffer from neuropathic pain. Source: Pfizer, Inc. Side Effects of Lyrica The most common side effects of Lyrica are dizziness, sleepiness, dry mouth, swelling of hands and feet, blurred vision, weight gain and trouble concentrating. Patients with a history of drug or alcohol abuse may have a higher chance of misuse or abuse of Lyrica. FDA批准Lyrica的补充适应症 辉瑞公司近日宣布，Lyrica已被FDA批准为成人癫痫患者局限性发作的辅助治疗用药。这项批准意味着Lyrica可以在47个国家内用于神经病变性疼痛和癫痫的治疗。 　　 FDA是基于三项涉及1052个病人的双盲对照试验中对Lyrica作出扩大适应症批准的。在使用Lyrica治疗初期，尽管病人同时使用一到三种其他抗痫药物进行治疗，每月发病次数也达到10次左右。而用Lyrica作辅助治疗的病人局部发作频率减少比例达到51%。病人每天服用Lyrica的次数为2到3次。 　　 宾夕法尼亚医科大学神经病学教授Jacqueline French认为，目前市场对抗痫病药物的需求量非常大，因为近五年来一直没有新型抗癫痫药物问世。 　　 “对癫痫病发作频率的控制收效甚微会在心理和生理上对病人造成不良的影响，而这会大大降低他们的生活质量。在临床试验中，对于使用常规抗癫痫药物进行治疗但仍旧发作的病人，Lyrica能显著地减少他们发作的频率。” 　　 2004年12月FDA批准Lyrica作为糖尿病外周神经病变和疹后神经痛治疗药物。Lyrica是一种α--2-Δ--配体，具有新型作用机理，即能够抑制高度活跃的神经细胞。